GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (NAS:BPMC) » Definitions » Cyclically Adjusted PS Ratio

Blueprint Medicines (Blueprint Medicines) Cyclically Adjusted PS Ratio : 26.94 (As of May. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines Cyclically Adjusted PS Ratio?

As of today (2024-05-24), Blueprint Medicines's current share price is $102.39. Blueprint Medicines's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $3.80. Blueprint Medicines's Cyclically Adjusted PS Ratio for today is 26.94.

The historical rank and industry rank for Blueprint Medicines's Cyclically Adjusted PS Ratio or its related term are showing as below:

BPMC' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 12.63   Med: 22.91   Max: 28.21
Current: 26.99

During the past years, Blueprint Medicines's highest Cyclically Adjusted PS Ratio was 28.21. The lowest was 12.63. And the median was 22.91.

BPMC's Cyclically Adjusted PS Ratio is ranked worse than
87.55% of 506 companies
in the Biotechnology industry
Industry Median: 5.665 vs BPMC: 26.99

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Blueprint Medicines's adjusted revenue per share data for the three months ended in Mar. 2024 was $1.506. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $3.80 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Blueprint Medicines Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Blueprint Medicines's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Cyclically Adjusted PS Ratio Chart

Blueprint Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 25.09

Blueprint Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 13.73 25.09 24.93

Competitive Comparison of Blueprint Medicines's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Blueprint Medicines's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Cyclically Adjusted PS Ratio falls into.



Blueprint Medicines Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Blueprint Medicines's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=102.39/3.8
=26.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Blueprint Medicines's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Blueprint Medicines's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.506/131.7762*131.7762
=1.506

Current CPI (Mar. 2024) = 131.7762.

Blueprint Medicines Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.026 99.621 0.034
201506 0.157 100.684 0.205
201509 0.128 100.392 0.168
201512 0.171 99.792 0.226
201603 0.253 100.470 0.332
201606 0.260 101.688 0.337
201609 0.226 101.861 0.292
201612 0.270 101.863 0.349
201703 0.176 102.862 0.225
201706 0.152 103.349 0.194
201709 0.206 104.136 0.261
201712 0.041 104.011 0.052
201803 0.022 105.290 0.028
201806 0.945 106.317 1.171
201809 0.025 106.507 0.031
201812 0.023 105.998 0.029
201903 0.017 107.251 0.021
201906 0.105 108.070 0.128
201909 0.187 108.329 0.227
201912 1.047 108.420 1.273
202003 0.117 108.902 0.142
202006 0.154 108.767 0.187
202009 13.122 109.815 15.746
202012 0.586 109.897 0.703
202103 0.372 111.754 0.439
202106 0.467 114.631 0.537
202109 0.412 115.734 0.469
202112 1.814 117.630 2.032
202203 1.058 121.301 1.149
202206 0.613 125.017 0.646
202209 1.104 125.227 1.162
202212 0.648 125.222 0.682
202303 1.053 127.348 1.090
202306 0.951 128.729 0.974
202309 0.932 129.860 0.946
202312 1.182 129.419 1.204
202403 1.506 131.776 1.506

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Blueprint Medicines  (NAS:BPMC) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Blueprint Medicines Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines (Blueprint Medicines) Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
Executives
Ariel Hurley officer: Principal Accounting Officer C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Jeffrey W. Albers director, officer: CEO & President BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Christopher K. Murray officer: SVP, Technical Operations C/O BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Fouad Namouni officer: President, R and D 535 BOYLSTON ST., 2ND FLOOR, BOSTON MA 02116
L. Becker Hewes officer: Chief Medical Officer C/O BLUEPRINT MEDICINES, CORPORATION, CAMBRIDGE MA 02139
Percy H. Carter officer: Chief Scientific Officer C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Philina Lee officer: Chief Commercial Officer C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Christina Rossi officer: Chief Commercial Officer 45 SIDNEY STREET, BLUEPRINT MEDICINES CORPORATION, CAMBRIDGE MA 02139
Tracey L Mccain officer: EVP and Chief Legal Officer C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Michael Landsittel officer: Principal FAO BLUEPRINT MEDICINES CORP., 214 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Debra Durso-bumpus officer: Chief People Officer C/O BLUEPRINT MEDICINES CORORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Kate Haviland officer: Chief Business Officer BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
John Tsai director BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
George Demetri director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142